Arovella Therapeutics Ltd (ala) Logo

Arovella Therapeutics Ltd (ALA)

___:___ · Healthcare

ALA Chart


ALA's Principal Activity is the pharmaceutical development and to acquire new platforms that align with oncology and conditions that affect the central nervous system.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -45.14%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,752 of 2,420
Sector Rank 158 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies LSH / CP1 / ADR
EPS -$0.017
DPS $0.00
Book Value Per Share $0.02

Broker Consensus

ALA is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Arovella Therapeutics Limited (ALA, formerly Suda Pharmaceuticals Ltd)is a biotechnology company focused on developing therapies to treat human disease. Arovella's two focus areas are oncology and conditions that impact the central nervous system. Arovella is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers.

Incorporation Details

Incorporated in Perth on 21/12/1999.

Corporate Details

Head Office Osborne Park WA 6017
Registry Automic Pty Ltd
Auditor HLB Mann Judd
Date Listed 24 Jan 2002

Upcoming Calendar (Forecasted)

Date Event
30/08/2022 Report (Prelim)
29/09/2022 Report (Annual)
27/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Elizabeth Stoner Non-Executive Director Nov 2021

Dr Elizabeth Stoner

Non-Executive Director

Dr Stoner has over 30 years of experience in the life-sciences sector, spanning earlystage research, drug development and venture investing. She is currently Executive Partner at MPM Capital, with over two decades of experience founding and investing in life-sciences companies that seek to translate scientific innovations into cures for major diseases. In her role, Dr Stoner serves as a clinical advisor to several of MPM Capital's portfolio companies, including AlloVir, and Rhythm Pharmaceuticals. Additionally, Dr Stoner served as the interim CEO of the cell therapy biotechnology company, Semma Therapeutics, which was acquired by Vertex in 2019 for US$950 million. Prior to joining MPM Capital, Dr Stoner was Senior Vice President of Global Clinical Development Operations at Merck Research Laboratories where she was responsible for its clinical development activities in more than 40 countries. While at Merck, she also oversaw the clinical development activities of its Japanese subsidiary. Previously, she led the 5- alpha reductase clinical development program. Dr Stoner currently serves on the board of Triplett Therapeutics. She is also a member of the Albert Einstein College of Medicine Board of Governors, and the Weill Cornell Medical College Clinical and Translational Science Center External Advisory Board. Prior to joining the biopharma industry, she was an Assistant Professor of Paediatrics at Cornell University Medical College.

Dr Debora Barton Non-Executive Director Aug 2021

Dr Debora Barton

Non-Executive Director

Dr Barton has over 20 years' experience in the field of oncology. After practicing oncology as a physician and clinical trial investigator, she spent five years at Novartis and five years at Celgene in roles of increasing responsibilities in Medical Affairs and Clinical Development. Dr Barton has experience working with cell therapy products, formerly as the Senior Vice President, Clinical and Head of Safety, of the clinical stage company, Iovance, who are developing T cell therapies for cancer treatment. Dr Barton is currently the Chief Medical Officer of Carisma Therapeutics, a clinical stage biopharmaceutical company, developing innovative immunotherapies including the first in class chimeric antigen receptor (CAR) macrophages for the treatment of certain cancers. Dr Barton is a member of the Manhattan Board of Directors for the American Cancer Society and is also a member of the Medical Advisory Board of the Tigerlily Foundation, a national breast cancer foundation providing education, awareness, advocacy and hands-on support to young women before, during and after breast cancer.

Mr Phillip Hains Company Secretary Jul 2020
Dr Michael Baker Chief Executive Officer,Managing Director Jan 2020

Dr Michael Baker

Chief Executive Officer,Managing Director

Dr Baker has over 15 years of experience in scientific research, drug development and venture investing. He was an Investment Manager with leading Australian life science fund, BioScience Managers, responsible for deal sourcing from networks, conferences, universities and research institutes. He also conducted due diligence to shortlist investment opportunities and played a role in managing portfolio companies. He is Member of Risk Committee and HR Committee.

Mr Paul Alex Hopper Non-Executive Chairman,Non-Executive Director Sep 2019

Mr Paul Alex Hopper

Non-Executive Chairman,Non-Executive Director

Mr Hopper has over 20 years' experience in the management and funding of biotechnology and healthcare public companies both as Chief Executive Officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas with focus on immunotherapy and cancer vaccines. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. He is Director of Radiopharm Theranostics Limited, since 11 February 2021, Chimeric Therapeutics Limited (ASX: CHM), since 2 February 2020, Imugene Limited, since 31 October 2012, Scopus BioPharma Inc (New York) (Stat3 technology), since December 2020. He is Chair of the HR Committee and Member of Risk Committee.

Mr David Simmonds Non-Executive Director Mar 2019

Mr David Simmonds

Non-Executive Director

Mr Simmonds was a senior audit partner with Ernst & Young from 1989 to 2017. From 2008 to 2013, David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. As an audit partner, David was involved in several businesses including Ramsay Health Care Ltd, John Fairfax Holdings and Commonwealth Bank of Australia and also was audit partner for the Australian operations of the leading US technology companies Hewlett Packard, Sun Microsystems and Oracle. David was a member of the Board and chaired the Audit, Risk and Finance Committee of MS Research Australia. He is Chair of Risk Committee and Member of HR Committee.

Director Transactions

ALA directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
16/03/22 Elizabeth Stoner Issued 263,157 $0.038 $9,999 Placement
16/03/22 Debora Barton Issued 263,157 $0.038 $9,999 Placement
16/03/22 David Simmonds Issued 263,157 $0.038 $9,999 Placement
16/03/22 Michael Baker Issued 789,473 $0.038 $29,999 Placement
16/03/22 Paul Hopper Issued 3,263,156 $0.038 $123,999 Placement
16/03/22 Paul Hopper Issued 631,578 $0.038 $23,999 Placement
16/12/21 Elizabeth Stoner Issued 2,400,000 $0.04 $96,000 Issue of options
16/12/21 Debora Barton Issued 2,400,000 $0.04 $96,000 Issue of options
16/12/21 Paul Hopper Issued 6,000,000 $0.04 $240,000 Issue of options
15/12/21 Michael Baker Buy +650,000 $0.039 $25,350 On-market trade
15/12/21 Paul Hopper Buy +1,000,000 $0.04 $40,000 On-market trade
11/11/21 Michael Baker Issued 8,000,000 $0.041 $328,000 Issued under employee share plan

Director Interests

The current holdings of ALA directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Elizabeth Stoner 16/03/2022 263,157 N/A 2,400,000 N/A
Debora Barton 16/03/2022 263,157 N/A 2,400,000 N/A
Michael Baker 16/03/2022 0 2,256,140 10,800,000 N/A
David Simmonds 16/03/2022 513,157 N/A N/A N/A
Paul Hopper 16/03/2022 1,866,247 4,378,712 7,600,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Sep 15, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Zerrin Investments Pty Ltd 17,010,000 3.54%
UBS Nominees Pty Ltd 15,064,640 3.13%
Kamala Holdings Pty Ltd 11,500,000 2.39%
Chelsea Investments (WA) Pty Ltd 10,000,000 2.08%
Scintilla Strategic Investments Limited 6,500,000 1.35%
Mr James Bradley Richardson 6,325,000 1.32%
Mr Steve John Wicks 5,796,464 1.21%
Bamber Investments Pty Ltd 5,611,446 1.17%
BNP Paribas Nominees Pty Ltd 5,575,283 1.16%
Mrs Michelle Suzanne Quinsee 5,350,000 1.11%
PCAS (Australia) Pty Ltd 5,000,000 1.04%
Alexander Holdings (Wa) Pty Ltd 5,000,000 1.04%
Klosters Holdings Pty Ltd 4,500,000 0.94%
Mr Mark Andrew Duncan-Smith & Mr Benjamin Ronald Smith 4,377,898 0.91%
Pulner Pty Ltd 4,350,000 0.90%
Termco Pty Ltd 4,200,000 0.87%
Altor Capital Management Pty Ltd 4,130,000 0.86%
Mr Craig Graeme Chapman 4,027,778 0.84%
Demasiado Pty Ltd 3,900,000 0.81%
Seafield Superannuation Pty Ltd 3,593,567 0.75%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 703 676 421 1,286 678 3,764

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Merchant Funds Management Pty Ltd 28/01/2022 47,416,666 7.89

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
28-01-22 Merchant Funds Management Pty Ltd 47,416,666 -- 7.89

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
ALA Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.